SABR for Comprehensive Treatment of Oligometastatic Tumours (COMET)
Research type
Research Study
Full title
Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumours (SABR-COMET): A Randomized Phase II Trial
IRAS ID
135133
Contact name
Stephen McKay
Contact email
Sponsor organisation
NHS Greater Glasgow & Clyde
Clinicaltrials.gov Identifier
Duration of Study in the UK
1 years, 7 months, 1 days
Research summary
Stereotactic ablative radiotherapy (SABR) has emerged as a new treatment option for patients with oligometastatic disease. SABR delivers precise, high-dose, hypofractionated radiotherapy, and achieves excellent rates of local control. Survival outcomes for patients with oligometastatic disease treated with SABR appear promising, but conclusions are limited by patient selection, and the lack of adequate controls in most studies. The goal of this multicenter randomized phase II trial is to assess the impact of a comprehensive oligometastatic SABR treatment program on overall survival and quality of life in patients with up to 5 metastatic cancer lesions, compared to patients who receive standard of care treatment alone.
REC name
West of Scotland REC 3
REC reference
14/WS/1028
Date of REC Opinion
28 Jul 2014
REC opinion
Further Information Favourable Opinion